Skip directly to content

Board of Directors

David de Graaf, Ph.D., Chairman


Dr. David de Graaf joined Selventa in 2010 to define the company’s scientific strategy, direction and general operations. Additionally, he is responsible for developing key partnerships that will enhance the company’s significance.
Previously, Dr. de Graaf served as the Vice President of Biotherapeutics and Integrative Biology at Boehringer-Ingelheim, where he built a successful portfolio of clinical candidates, initiated key collaborations as well as managed scientific leadership and site operations. He also held roles with increasing responsibilities at Pfizer, AstraZeneca and the Whitehead/MIT Center for Genome Research with a focus on bringing innovative systems biology approaches to the early pipeline.

Dr. de Graaf completed his postdoctoral fellowship at the Weizmann Institute of Science in Rehovot, Israel in pharmacogenomics of human olfactory systems. He also earned a Ph.D. in mammalian genetics from The University of Illinois at Chicago and a Masters of Science degree in evolutionary genetics from the University of Utrecht in the Netherlands. He was awarded a Feinberg Fellowship and is invited frequently to speak at scientific conferences.

[back to top]

Jim Matheson, Director


Mr. Jim Matheson joined the Selventa Board of Directors in 2005 and became Chairman in 2008. In his current role, he helps define the company’s strategic vision and brings value to Selventa’s customers and prospects based on his 20 years of technology and leadership experience.

Since becoming a General Partner with Flagship Ventures in 2000, Mr. Matheson focused on creating and funding new ventures in special technologies, sustainability and clean technology fields. He has held several roles designing, engineering and deploying sophisticated technology platforms. Previously, Mr. Matheson, a retired Commander in the U.S. Naval Reserves, served as a Navy F-14 and FA-18 pilot. He also had extensive experience in emerging aircraft and weapons system design, testing and procurement, and was involved deeply in many of the military’s IT modernization initiatives.

Mr. Matheson received an M.B.A. from The Harvard Business School and a Bachelor of Science degree in systems engineering with honors from The United States Naval Academy.

Harry Wilcox, Director


Harry Wilcox joined the Selventa Board of Directors in 2014. His career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has served on several Boards of Directors. In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures.

As COO and General Partner at Flagship Ventures, Harry is responsible for the operational management of Flagship's VentureLabsTM unit, serves as a member of Flagship's investment committee, and oversees the firm's financial operations and LP relations/fundraising.  He was a board member of Accuri Cytometers prior to its successful sale to Becton Dickinson.  He also plays a role as board member or advisor to select portfolio companies and is currently a board member of BG Medicine, Celexion, Quantum Designs, Seahorse Bioscience, Selventa, Seventh Sense Biosystems, Tangent Medical Technologies, Inc. and T2 Biosystems.

[back to top]

Michael Grey, Director


Mike Grey joined the Selventa Board of Directors in 2011. He has over 30 years of experience in the biopharmaceutical industry.

Mr. Grey is currently a Venture Partner at Pappas Ventures and CEO of Lumena Pharmaceuticals, a private biotech company. Prior to joining Pappas Ventures, he held multiple Chief Executive Officer positions in the pharmaceutical industry. He served as the President and CEO of Auspex Pharmaceuticals, CEO of SGX Pharmaceuticals (formerly Structural GenomiX) which was eventually sold to Eli Lilly, and President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He was also President of BioChem Therapeutics, the pharmaceutical arm of BioChem Pharma. Prior to these, Mr. Grey held various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President of Corporate Development and Director of International Licensing. Mr. Grey is a board member at BioMarin Pharmaceutical.

He received a Bachelor of Science in chemistry from the University of Nottingham in the United Kingdom.

[back to top]